BST-2123 is under clinical development by Bostal Drug Delivery Co and currently in Phase I for Diabetes. According to GlobalData, Phase I drugs for Diabetes have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BST-2123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BST-2123 overview

BST-2123 is under development for the treatment of diabetes. It is administered through oral route in the form of tablet.

Bostal Drug Delivery Co overview

Bostal Drug Delivery Co is engaged in the research and development of generic drugs including injectable, liposome, insoluble drugs, gastroretentive and sustained release preparations used for the treatment of cardiovascular, metabolic and psychiatric disorders. The company is headquartered in Guangzhou, Guangdong, China.

For a complete picture of BST-2123’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.